DEKAVIL (F8-IL10)

DEKAVIL (F8-IL10)

Dekavil is an immunocytokine consisting of a targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10).

Dekavil has demonstrated an impressive ability to selectively localize to arthritic sites in-vivo, potently inhibiting arthritic progression. Dekavil is expected to be superior to non-conjugated recombinant IL10, a biopharmaceutical which has extensively been tested in Phase II clinical trials in chronic inflammation and which has shown efficacy for the treatment of rheumatoid arthritis.

Dekavil has entered Phase II clinical trials in combination with methotrexate for the therapy of Rheumatoid Arthritis. Dekavil has been exclusively licensed to Pfizer Inc., and investigations in IBD indications are being considered.

SELECTED REFERENCES

EULAR conferences 2013, 2014, 2015
Doll et al., (2013) Arthritis Res. Ther., 15, R13826, 2344-52;
Schwager et al., (2011) Human Reprod., 26, 2344-52;
Schwager et al., (2009) Arthritis Res. Ther., 11, R142;
Trachsel et al., (2007) Arthritis Res. Ther., 9, R9;
Trachsel et al., (2007) J. Invest. Dermatol., 127, 881-886.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy
X